You are here
Genetics Policy Institute
The Genetics Policy Institute (GPI) is a leading promoter and defender of stem cell research and other cutting-edge medical research targeting cures. We are the catalyst and provide leadership to the Pro-Cures Movement, an influential global network of stakeholders - from patient-advocacy to science and industry.
GPI pursues this mission through co-sponsorship and management of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, advocating, organizing events, speaking engagements, teaching initiatives, and strategic collaborations. We create positive public awareness for stem cell research and regenerative medicine.
GPI maintains science and legal advisory boards comprised of leading stem cell researchers, disease experts, ethicists and legal experts as well as a dedicated fulltime staff of policy, business, science and communication experts that are available to educate the public and media on stem cell issues. GPI serves as the foremost channel of knowledge between the world leading stem cell experts, patient advocates and those who make policy for the general public.
The World Stem Cell Summit, produced by the Genetics Policy Institute (GPI), is the largest interdisciplinary networking meeting of stem cell stakeholders that unites the diverse regenerative medicine community. With the overarching purpose of fostering biomedical research and investments targeting cures, the Summit is the top conference charting the future of this burgeoning field.
The program of the World Stem Cell Summit provides the research, industry, economic and societal context for understanding how all of the pieces of the stem cell puzzle fit together. The agenda features more than 150 speakers and 50 hours of in-depth presentations. Supported by 200 sponsors, exhibitors, endorsing organizations and media partners, the Summit is a three-day showcase of innovation, insight and inspiration.
The Summit's industry track, standing alone, is the largest stem cell business conference in North America with top leaders from cell therapy, biotechnology, tool, devices and pharma in attendance on a program that covers in-depth the issues pertinent to translating basic research into cures, including discussions on regulatory pathways, cell standardization, reimbursements, financing, venture capital and economic development.